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64 The Journal of Thoracic and CardiovObjective: Although resection is not the standard of care in treating small cell lung
cancer, new platinum drugs and modern staging have allowed the role of surgery to
be reevaluated.
Methods: We reviewed our institutional experience of 1415 patients with small cell
lung cancer from 1976 to 2002 among whom 82 (6%) underwent surgery with
curative intent.
Results: Median age at surgery was 62 years, and small cell lung cancer of mixed
morphology represented 14 of 82 (17%). Treatment consisted of surgery alone in
11% of cases (9/82), surgery with neoadjuvant therapy in 22% (18/82), and surgery
with adjuvant therapy in 55% (45/82). Prophylactic cranial irradiation was given to
23% (19/82). The 5-year survival of the entire cohort was 42%. The 5-year survival
of patients receiving adjuvant chemotherapy (n  41) was significantly different
according to whether patients had received platinum or nonplatinum regimens (68%
vs 32.2%, P  .04). Among patients with stage I disease who received adjuvant
chemotherapy (n  24), the 5-year survivals for patients receiving platinum and
nonplatinum chemotherapy were 86% and 42%, respectively (P  .02). If patients
who received either neoadjuvant or adjuvant therapy (n  56) were considered, the
5-year survival was significantly better for platinum than for nonplatinum chemo-
therapy (62% vs 36%, P  .05). The 5-year survival was also better for those
undergoing lobectomies (n  52) than for those with limited resections (n  15,
50% vs 20%, P  .03). Survival outcomes also differed by gender, with female
patients having a 5-year survival advantage over male patients (60% vs 28%, P 
.004).
Conclusion: These results support a reevaluation of the role of surgery in the
multimodality therapy for small cell lung cancer, which currently includes only
radiotherapy and chemotherapy.
ascular Surgery ● January 2005
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TSArecent analysis of the Surveillance, Epi-demiology, and End Results database ob-served that small cell lung cancer (SCLC)now accounts for about 14% of all newcases of lung cancer.1 This represents ap-proximately 26,000 patients in the United
States alone. Because of SCLC’s high case-fatality rate,
more than 90% of patients, or about 23,500 people in this
country, annually die of their disease. Tobacco exposure is
more closely associated with SCLC than with any other
cancer histologic type. Of all histologic types, SCLC is the
most sensitive to both chemotherapy and radiotherapy.2,3
Despite this sensitivity, the overall 5-year survival is poor,
and there is a critical need for new therapeutic options.
The role of surgery in SCLC is controversial. Two large,
randomized, prospective trials of surgery versus radiother-
apy organized by the British Medical Research Council in
the 1960s and 1970s reported that surgery and radiotherapy
were equally ineffective for limited stage SCLC.4,5 Propo-
nents of surgery argue that the Medical Research Council
studies included very few patients with very early stage
(T1-2 N0) disease, and that this is precisely the patient
population most likely to benefit from surgery.
Since the Medical Research Council studies were per-
formed, more than 3 decades ago, the advent of new,
powerful diagnostic tools, such as spiral computed tomog-
raphy and positron emission tomography, along with tradi-
tional mediastinoscopy allow for very limited disease to be
more readily identified and to be adequately staged preop-
eratively. In addition, since the early 1980s, multiagent
platinum-based chemotherapeutic regimens have been iden-
tified with significant activity in SCLC with, a response rate
as high as 80%.6 Radiotherapy options have also increased
significantly since that time, with consideration of various
radiation port volumes, intensity modulation, and explora-
tion of several alternative doses and schedules.
We hypothesized that in the modern era of multimodality
cancer treatment, surgery as a technique for maximizing
local control would confer a survival advantage for selected
patients with SCLC if used with platinum based chemother-
apy, optimal delivery of radiotherapy and prophylactic cra-
nial irradiation. We examined our experience during the last
28 years at the Johns Hopkins Hospital to help define the
role of surgery in the modern therapy of SCLC.
Patients and Methods
Population
Approval to perform this study was obtained from the institutional
review board of the Johns Hopkins Medical Institutions. The study
population comprised 82 patients with primary SCLC who under-
went pulmonary resection with curative intent (Current Procedural
Terminology codes 32440-32445 and 32480-32488). These cases
were identified out of a total of 1415 patients who had small cell
bronchogenic carcinoma (International Classification of Diseases,
The Journal of ThoracNinth Revision, Clinical Modification codes 8041/3-8045/3) diag-
nosed between January 1, 1976, and December 31, 2002. Because
retrospective survival studies of SCLC have been criticized for
relying on histologic diagnoses made in the 1970s, when distinc-
tions between SCLC and atypical carcinoid tumors were occasion-
ally blurred,7 a board-certified pathologist (W.W.) reviewed all
SCLC cases by standard light microscopy to ensure that all pa-
tients did have small cell carcinoma of the lung consistent with the
original pathology reports.
We included all operations performed with curative intent and
excluded patients if they had (1) resection for pulmonary metas-
tases, (2) operation for diagnostic biopsy, or (3) staging thoracos-
copy. Eastern Cooperative Oncology Group performance status
data on individual patients were not analyzed.
Patient Clinical Variables and Outcomes
Intraoperative mediastinal lymph node sampling was performed as
systematic sampling of levels R2, R4, 7, R8, R9, and R10 on the
right side, and 5, 6, 7, L8, and L9 on the left side, if present. Nodes
were labeled according to the American Thoracic Society lymph
node mapping system. All patients who underwent segmental or
greater resections also underwent mediastinal nodal sampling.
Among the 10 wedge resections, in only 1 case was nodal sam-
pling performed. For the purposes of this study, all patients un-
derwent staging according to the 1997 TNM classification criteria,
which was reported as pathologic staging except in the case of the
9 patients with wedge resection, for whom staging was reported as
cTNM because of a lack of adequate mediastinal sampling. Those
who underwent resection before 1997 had their disease reclassified
according to the new pTNM system. There were 18 patients who
received neoadjuvant therapy, but all had their disease classified
according to the pTNM staging determined after resection. Defin-
itive data on which patients in the neoadjuvant group underwent
preoperative sampling of mediastinal lymph nodes, either by trans-
bronchial fine needle aspiration or by mediastinoscopy, were in-
complete (mainly because the preoperative sampling was per-
formed outside our institution) and do not factor into this analysis.
Similarly, data regarding objective response rates to neoadjuvant
therapy and the Eastern Cooperative Oncology Group performance
status data of the patients were incomplete and consequently not
analyzed.
Although all patients with SCLC were referred for consider-
ation of adjuvant therapy, 19 patients did not receive any addi-
tional postoperative treatment. Specific adjuvant treatment infor-
mation was unavailable for 10 patients referred back to their
primary care physicians without further follow-up. Of the 9 pa-
tients who underwent surgery alone, 4 refused any adjuvant ther-
apy and 5 died before completion of the chemotherapy recom-
mended by the medical oncologist.
Adjuvant treatment was recorded as radiotherapy, chemother-
apy, or both as appropriate. Because multiple chemotherapeutic
drugs were used during the 3 decades of the study period, the
chemotherapy regimens were codified as either platinum or non-
platinum. We chose January 1, 1987, as a time point of signifi-
cance because this date represented the first time in our hospital
when platinum-based drugs were in widespread use, and it is
conveniently positioned near the halfway point of our study. Al-
though postoperative radiotherapy was given mainly to patients
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TSwith nodal disease, 6 of 48 patients with stage I disease (12%)
were treated with adjuvant radiotherapy. Prophylactic cranial irra-
diation was performed on 19 patients, including 8 patients with
stage I disease.
Patients’ data were obtained to their last date of follow-up or
until death. Vital status data were provided by the National Death
Index of the National Center for Health Statistics. Survival was
defined as the interval between date of surgery and date of death or
last follow-up. Death included all causes and was not specifically
cancer related.
Statistical Analysis
The Kaplan-Meier product limit method and the log-rank test were
used for survival analysis. The association of factors with time to
event end points was estimated with the Cox proportional hazards
model for multivariate analysis. Comparisons of continuous and
dichotomous variables between groups were performed with the
Student t test (2-tailed) and 2 tests, respectively. All analyses
were accomplished with the STATA statistical software package
TABLE 1. Characteristics of treatments for SCLC before an
Treatment types Total
Overall
Surgery alone 9 (10.9%)
Postsurgical treatment unspecified 10 (12.2%)
Neoadjuvant therapy 18 (22%)
Adjuvant therapy 45 (54.9%)
Surgery alone (n  9)
Died before additional treatment 5 (56%)
Refused additional treatment 4 (44%)
Neoadjuvant therapy (n  18)
Chemotherapy alone 16 (88.9%)
Chemotherapy plus radiation 2 (11.1%)
Neoadjuvant chemotherapy (n  18)
Platinum 6 (33.3%)
Nonplatinum 9 (50%)
Unspecified chemotherapy 3 (16.7%)
Adjuvant therapy (n  45)
Chemotherapy alone 16 (35.6%)
Radiation therapy alone 4 (8.9%)
Chemotherapy plus radiation 25 (55.6%)
Adjuvant chemotherapy (n  41)
Platinum 17 (41.5%)
Nonplatinum 24 (58.5%)
Adjuvant radiation therapy (n  29)
Chest 10 (34.5%)
Prophylactic cranial 12 (41.4%)
Chest plus prophylactic cranial 7 (24.1%)
Surgical procedures (n  82)
Lobectomy 52 (63.4%)
Pneumonectomy 12 (14.6%)
Wedge resection 10 (12.2%)
Segmentectomy 5 (6.1%)
Bilobectomy 3 (3.7%)(Stata Corporation, College Station, Tex).
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Demographic Characteristics
Median age was 62 years, with 57% being male. Most patients
were chronic smokers, with a median of 50 pack-year smok-
ing. About 87% of patients had a history of tobacco use, and
56% were active cigarette smokers. The resection rate of
SCLC was 5.7% (82/1415). Most patients did not have a
confirmed diagnosis of SCLC before resection and were taken
to surgery for small pulmonary nodules suspected of being
cancerous. SCLC lesions elicited symptoms in only 54% of
patients. A total of 46% of patients had pulmonary nodules
found incidentally on chest radiography during routine diag-
nostic workup for a coincidental illness. Forty-eight patients
(59%) underwent resection for stage I disease. Three patients
had their disease upstaged to stage IIIB or IV because of
metastatic lesions outside of the index lobe of the primary
tumor. Mixed histologic types were observed in 14 tumors
ter 1987 (n  82)
<1987 >1987 P value
.53
4 (8.7%) 5 (13.9%)
4 (8.7%) 6 (16.7%)
10 (21.7%) 8 (22.2%)
28 (60.9%) 17 (47.2%)
.294
3 (75%) 2 (40%)
1 (25%) 3 (60%)
.867
9 (90%) 7 (87.5%)
1 (10%) 1 (12.5%)
.003
0 (0%) 6 (75%)
8 (80%) 1 (12.5%)
2 (20%) 1 (12.5%)
.438
8 (28.6%) 8 (47.1%)
3 (10.7%) 1 (5.9%)
17 (60.7%) 8 (47.1%)
.0001
4 (16%) 13 (81.3%)
21 (84%) 3 (18.7%)
.741
6 (30%) 4 (44.4%)
9 (45%) 3 (33.3%)
5 (25%) 2 (22.2%)
.616
28 (60.9%) 24 (66.7%)
9 (19.6%) 3 (8.3%)
5 (10.9%) 5 (13.9%)
2 (4.4%) 3 (8.3%)
2 (4.4%) 1 (2.8%)d af(17%), with the predominant mixed histologic cell types being
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TSa combination of small cell and large cell phenotypes. Lobec-
tomy or greater resection was performed in 82% of patients.
Surgery
All operations were elective. Most patients underwent
lobectomy (n  52, 63%), because that was the preferred
operation if the lesion was completely resectable, the
general medical condition of the patient was acceptable,
and respiratory mechanics and gas exchange were satis-
factory. Twelve patients underwent pneumonectomy, and
3 patients underwent bilobectomy. Ten patients under-
went only wedge resection. The wedge resection was
carried out during the 1970s or 1980s (when this was
considered standard practice) in 6 cases, in another 3
cases intraoperative decisions prompted a lesser resection
because of concerns about the patient’s ability to tolerate
a lobectomy, and in 1 case the wedge resection was
preferred for undocumented reasons. There was a consis-
tent distribution of operative procedures throughout the
study period, with 45 of 82 (55%) before 1987 and 37 of
82 (45%) after 1987 (Table 1). There were no evident
changes in the relative frequencies of the various surgical
procedures performed before or after 1987.
Table 1 outlines the various neoadjuvant and adjuvant
therapies administered during the study period. Neoadju-
vant therapy was given to 18 patients. After exclusion of
patients with neoadjuvant therapy, those with surgery alone,
those who received radiation therapy alone, and those for
whom specific adjuvant therapy information was unavail-
able, 41 patients formed the cohort who received adjuvant
chemotherapy. In 25 of these 41 cases, adjuvant chemother-
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Figure 1. Kaplan-Meier survival curves of all patient
(n 82) by pathologic stage of the tumor found at surge
N0) who had complete surgical resection was signific
stage IV disease (58% vs 18%, 23%, and 0%, respectivapy was given with radiation therapy. Nineteen patients
The Journal of Thoracreceived prophylactic cranial irradiation, and 17 patients
had adjuvant chest radiation. There was no difference in
distribution of frequency of radiation therapy before versus
after 1987 (Table 1).
Survival
There was only 1 postoperative death, that of a patient with
a pulmonary embolus at postoperative day 13, giving a
30-day surgical mortality of 1.2%. Data on postoperative
complications were available for 62% of patients (51/82).
There were 7 nonfatal complications, all involving the car-
diorespiratory system, including 1 case of pneumonia, 2
cases of dysrhythmia, and 4 cases of air leakage. The mean
follow-up period for the entire study population was 2.6
years. The median survival for all patients was 2.0 years,
with overall 1-, 5-, and 10-year survivals of 78%, 42%, and
36%, respectively.
The 5-year survival for patients with stage I SCLC (T1-2
N0) who underwent complete surgical resection was signif-
icantly better than for those patients with stage II, stage III,
or stage IV disease (58% vs 18%, 23%, and 0%, respec-
tively P  .001; Figure 1). Another subgroup with good
long-term survival was the group of 41 patients who re-
ceived postoperative adjuvant chemotherapy, with overall
1-, 3-, and 5-year survivals of 82%, 50%, and 47%, respec-
tively. By stage, the 5-year survivals for the 41 patients
receiving adjuvant chemotherapy were 63%, 25%, and 25%
for stages 1, 2, and 3, respectively (Table 2). In particular,
the 5-year survival for these 41 patients was significantly
different according to whether they had received platinum
versus nonplatinum chemotherapy (68.0% vs 32.2%, re-
After Surgery
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TShad stage I disease and received adjuvant chemotherapy are
considered (n  24), the 5-year survival of patients with
stage I disease who had platinum adjuvant chemotherapy
was 85.7%, versus only 41.7% (P  .02) for those who
received nonplatinum chemotherapy (Figure 2).
If all patients who received any form of chemotherapy,
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Figure 2. Kaplan-Meier survival curves of patients wit
24) according to whether platinum or nonplatinum ch
received platinum therapy was 85.7%, versus 41.7% fo
TABLE 2. Selected published results for the 5-year surviva
Reference
Study
period
Shields et al8 (1982) 1957–1977
Meyer et al9,10 (1984) —
Wada et al11 (1985) 1976–1991
Osterlind et al12 (1986) 1973–1981
Ohta et al13 (1986) 1973–1985
Maassen and Greschuchna14 (1985) 1962–1979
Shepherd et al15 (1988) 1976–1988
Hara et al16 (1991) 1972–1989
Macchiarini et al17 (1991) 1980–1986
Davis et al18 (1993) 1981–1989
Karrer et al19 (1995) 1989–1993
Lucchi et al20 (1997) 1975–1995
Cataldo et al21 (2000) 1982–1992
Suzuki et al22 (2000) 1991–1996
Badzio et al23 (2004) 1984–1996
Brock et al (2004) 1975–2003
*N0 and N1 combined.
†Three-year survival.
‡N1 and N2 combined
§Four-year survival.
Current study.either neoadjuvant or adjuvant (n  56), were considered,
68 The Journal of Thoracic and Cardiovascular Surgery ● Januathe 5-year survival was significantly better for those who
were treated with platinum versus nonplatinum chemother-
apy (62% vs 36%, P  .05). Eighteen patients received
neoadjuvant chemotherapy with a median survival of 3.4
years, or an overall 5-year survival of 48%. Our neoadju-
vant series was small and was not sufficiently powered to
rs After Surgery
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those receiving nonplatinum neoadjuvant chemotherapy
(50% vs 44%, respectively).
Because 1987 was the first year of widespread platinum
chemotherapy use in our institution, we analyzed our data
before and after 1987. This date also represented approxi-
mately the middle point of the study. Table 1 illustrates that
there were no differences during the study period in the
distribution of types of surgical resections that occurred, the
proportion of patients who were given neoadjuvant versus
adjuvant chemotherapy, and the number of patients who
received prophylactic cranial irradiation (19 patients). The
only significant difference in treatment observed was in the
proportion of patients who received platinum versus non-
platinum chemotherapy. We observed a statistically signif-
icant difference in survival between patients treated with
adjuvant chemotherapy (n  41) before and after 1987
(33% vs 71.4%, P  .03).
Survival was also dependent on the type of surgical
resection. The 5-year survival of those patients who under-
went lobectomy (n  52) was significantly better than that
of patients who underwent segmentectomy or wedge resec-
tion (n  15, 50% vs 20%, P  .03). This difference in
survival remained significant even after adjustment for
stage. Compared with male patients (n  47), female pa-
tients (n  35) had a survival advantage. The 1-, 3-, and
5-year survivals for male and female patients were 73%,
35%, and 28%, versus 86%, 63%, and 60%, respectively
(P  .004). Median survival for male patients was 16
months (range 1-221 months), versus 39 months for female
patients (range 2-216 months, P  .002). There were no
deaths observed among the 8 women with T1-2 N0 SCLC
who underwent complete surgical resection and received
adjuvant platinum chemotherapy. No differences were ob-
served between the sexes in the types of adjuvant chemo-
therapy treatment received.
Mixed cell variants represented 14 of 82 (17%) of the
study cases. Although the number of cases was small, the
5-year survivals of mixed cell variants was 68%, versus
38% for histologically pure SCLC (P  .20).
Multivariate Analysis
According to the Cox proportional hazards model of mul-
tivariate analysis, if the model was adjusted for the age of
the patient at time of surgery, then a patient’s stage, sex,
date of surgery, and type of surgical resection were all
strong, independent predictors of long-term survival (P 
.05). If a patient was male, he was 2.25 times more likely to
die. If a patient had more advanced disease than T1-2 N0,
the risk of death increased 2.8 times. Similarly, surgery
before 1987 was associated with poorer survival. Finally, if
a patient underwent a lesser pulmonary resection than a
lobectomy, the risk of death was 2.5 times greater than for
The Journal of Thoracpatients who underwent a lobectomy or greater resection.
Taken together, male patients with SCLC who before 1987
underwent a segmentectomy or wedge resection followed
by nonplatinum chemotherapy had a very poor long-term
survival.
Discussion
Highly selected patients with SCLC may benefit from sur-
gery and adjuvant chemotherapy, particularly if the chemo-
therapy is platinum based. In our adjuvant series, the sur-
gical candidates with SCLC who benefited most were
women with completely resectable T1-2 N0 disease who
then underwent platinum chemotherapy. Although the pa-
tients are few, the 5-year survival of 85.7% for those pa-
tients with stage I SCLC treated with surgery and postop-
erative platinum chemotherapy is similar to that historically
expected for surgical patients with stage I non–small cell
lung cancer (NSCLC) who do not receive adjuvant treat-
ment. Our data for SCLC also parallel findings that are well
established in the NSCLC literature indicating that surgical
resections less extensive than lobectomy result in inferior
survival of these patients.24
As observed in older studies, disease that had advanced
enough to involve hilar or mediastinal lymph nodes signif-
icantly reduced the 5-year survival of any patient.8,15,16,25
Our study achieved similar overall 5-year survivals by stage
as previous adjuvant series (Table 2). Our observations
confirm that if modern preoperative clinical staging can
correctly identify cT1-2 N0 SCLC, and if complete surgical
removal of the lesion is possible, platinum-based adjuvant
chemotherapy can lead to long-term survival. Moreover, our
5-year survival of 32.2% for nonplatinum chemotherapy
compares favorably with the 5-year survivals of many stud-
ies performed when that type of chemotherapy was the
standard of care.
The multivariate analysis identified patient factors such
as stage, date of surgery, surgical procedure, and sex as
significantly influencing survival outcome in this study.
Multiple studies have shown clinical and pathologic stage to
be important in SCLC.26 The date of procedure (before or
after 1987) was a surrogate marker for the availability of
adjuvant platinum chemotherapy. Administration of plati-
num chemotherapy appears to have been a substantial factor
in improving survival in patients with SCLC amenable to
surgical resection. In our series, lobectomy was an effective
means of locally controlling SCLC and may represent a
better mode than chemotherapy or radiotherapy for com-
pletely eradicating a small SCLC lesion.27 We agree with
Meyer’s commentary on the study of Shields and col-
leagues8 that surgical resection by itself is inadequate treat-
ment for SCLC of any TNM stage or for a mixed subtype
and that adjuvant chemotherapy is essential. Because our
data concerning specific sites for local and distant recur-
ic and Cardiovascular Surgery ● Volume 129, Number 1 69
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tions concerning local recurrence in this study. Although
several of our patients did receive prophylactic cranial irra-
diation, we also did not address the role of prophylactic
cranial irradiation in the inhibition of early development of
distant metastases in the brain.
Finally, it is possible that it was not the surgery itself, but
rather the selection factors enabling surgery, that played a
critical role in producing favorable outcomes. This study
was not randomized, and the surgical patients were highly
selected. Potential confounding variables, such as perfor-
mance status of individual patients or renal function, were
not assessed. Because this study was a hospital-based, ret-
rospective review spanning more than 2 decades and in-
volving many practitioners and multiple drug combinations
and dosages, we did not attempt to analyze individual doses
of chemotherapy. It is plausible that patients receiving plat-
inum chemotherapy were given more intensive therapies
than those who received nonplatinum regimens. There is
considerable evidence, however, to suggest that combina-
tions of chemotherapeutic drugs with platinum, such as
etoposide with cisplatin, may even have efficacy in patients
with refractory SCLC not responsive to nonplatinum regi-
mens such as cyclophosphamide, doxorubicin, and vincris-
tine.28,29
In summary, our data corroborate the historical literature
regarding surgical rates of resectability of SCLC, efficacy of
resecting early stage disease with surgery, and the impor-
tance of adjuvant chemotherapy. Because we analyzed our
data more than a decade after the introduction of platinum
chemotherapy, our findings suggest that platinum adjuvant
chemotherapy after a lobectomy led to excellent outcomes
in patients with early stage disease. These data indicate a
need to reconsider the current standard of care for select
patients with early stage SCLC and for a cooperative study
to reevaluate designing a randomized trial with modern
preoperative diagnostic procedures and current adjuvant
chemotherapy.
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Dr W. Roy Smythe (Temple, Tex). Thank you for the opportunity
to comment on this article. This is a thoughtful retrospective
evaluation of a select group of patients with SCLC undergoing
resection with curative intent during 26 years at a single institution.
The stated hypothesis was to determine whether surgery conferred
a survival advantage in the modern era of more effective neoad-
juvant and adjuvant therapies, including, importantly, platinum
chemotherapy.
I first have some comments. Even though the title of the article
is “Surgical Resection of Limited Disease Small Cell Lung Cancer
in the New Era of Platinum Chemotherapy: Its Time Has Come,”
I think it’s important to say that what I think is really meant is early
stage, rather than limited disease. I think this confusion of terms
may be one of the reasons that the results of the British Research
Council have been overgeneralized and overapplied, and many
people have not operated on patients with early stage disease. The
American Joint Committee on Cancer Staging actually defines
limited disease as stage I through IIIB, as compared with NSCLC.
So we’re really talking about stage I and stage II disease.
The second comment is that the hypothesis proposed obviously
can’t be answered without a randomized trial, although I think
there are some important caveats to be taken from this study
because we don’t have a lot of these patients for analysis. It is also
important to note that the American College of Chest Physicians’
evidence-based guidelines published in 2002 do suggest that it is
reasonable to resect limited disease SCLC defined as early stage,
stages I or II, and many of us have been practicing this for quite
some time.
I have three questions for you, Dr Brock. First, you talked about
the use of prophylactic cranial irradiation, but it appears that you
lumped prophylactic cranial irradiation with thoracic irradiation
with regard to evaluating its effectiveness or its impact on survival.
We know that prophylactic cranial irradiation decreases the rate of
central nervous system metastasis by about 50% and has a small
but real effect on survival. Did you look at this as a stand-alone
variable? I think 19 of your patients received prophylactic cranial
irradiation, and the remainder did not.
Dr Brock. Thank you very much, Dr Smythe, for those in-
sightful comments. I fully agree with both of your comments. I
think that our medical colleagues do speak a different language
from us when it comes to the staging of SCLC. This is partly
because our medical colleagues do not have the advantage of
routinely referring to the actual pathologic specimen with accom-
panying lymph nodes and, instead, have to rely on clinical and
radiologic impressions for staging. These clinical descriptors are
less precise and confuse the issue. We initially struggled in decid-
ing which nomenclature to use in the manuscript, but since this is
a surgical forum, we have used the pTNM staging system in the
final version of the submitted manuscript.
Let’s go to your question regarding prophylactic cranial irra-
diation and the thoracic irradiation. Our 5-year survival for our 19
patients with prophylactic cranial irradiation was approximately
60%. Our problem really was that we didn’t have the cause of
death for many of these patients. Therefore we don’t know how
many of these patients really had recurrences due to their brain
metastases.
The Journal of ThoracDr Smythe. For my second question, do you know the pattern
of recurrence? I guess what you’re saying is that you don’t know
the pattern of recurrence in these patients.
Dr Brock. We are trying to secure these data points for all 1400
patients with SCLC in our database. As of right now, we don’t
have this information.
Dr Smythe. For my last question, you say that the reason the
post-1987 group does better is that it’s a surrogate for use of
cisplatin-based chemotherapy, but isn’t it also possible that it’s a
surrogate for better staging? I would assume that between 1976
and 1987 you didn’t uniformly get computed tomographic scans, at
least of good quality, and certainly not positron emission tomo-
graphic scanning. So couldn’t that also just be a staging bias or a
surrogate for better staging?
Dr Brock. Yes, I agree with that comment. This is definitely
another interpretation of the data. Platinum-based chemotherapy
and better staging tools probably both contribute to better survival,
and I think that’s the premise of our discussion here. We would
like to use both of these modern tools in a randomized trial.
Dr William H. Warren (Chicago, Ill). Congratulations on a
fine article. This study covers quite a few years, and we are all
aware that there can be occasional cases in which the diagnosis of
SCLC is made on the basis of a fine-needle aspirate, but the final
diagnosis, made on the basis of the resected specimen, is different.
For the purposes of this study, was the surgically resected material
reviewed, including those specimens before 1987?
Dr Brock. That’s a great question. We had concerns that we
might even have had some carcinoids that were misclassified as
SCLC. After we initially identified the patients, the very next thing
we did was to have an independent review of all available tissues
by one of our lung pathologists. After re-reviewing about 90% of
the cases, he concluded that all the cases were correctly classified
either as SCLC or as a mixed variant (about 17% mixed variants).
Remarkably, he did not find any difference between his own
impression and what was reported back even in the early time
period of the study.
Dr Warren. Were any of them sterilized as a result of preop-
erative chemoradiotherapy?
Dr Brock. I did not look at how many had complete response.
We had 18 patients who had induction chemotherapy. I don’t know
the answer to that question.
Dr Steven J. Mentzer (Boston, Mass). I have just a quick
comment related to that histologic diagnosis. Because of the small
number of available patients, it may not be realistic to pursue a
randomized trial to look at the outcomes of a patient population
like this. If we can do genomic profiling and correlate the biologic
behavior, it may be possible to do a nonrandomized trial. Corre-
lating molecular features and pattern of failure, which is what Dr
Smythe and you alluded to earlier, may provide an opportunity to
study this question without the expense of a randomized trial.
Dr Brock. I agree that that’s a very good idea.
Dr Alec Patterson (St. Louis, Mo). We’re talking about a very
unusual lesion, I believe. I’m a little skeptical that you would ever
be able to mount or complete a randomized trial.
Dr Brock. I think that it’s a very uncommon lesion and I think
that various institutions have found that they don’t have this lesion
very often in their records. We were surprised that we had even 82.
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a while, but I think it could be done.
The other thing is that we found that the majority of these were
patients in whom the surgeon thought it was non–small cell lung
cancer and only after resection did he find out that it was SCLC.
I think that does happen, but you are right, it’s not a common,
everyday event.
Dr Thomas K. Waddell (Toronto, Ontario, Canada). It needs
to be said that there has been a randomized trial for this situation
of limited disease, although the criticism was always that it wasn’t
what you’re talking about, very limited disease. Maybe some of
the survivors of that era could comment. It was a negative trial.
There was no difference in the group treated with surgery.
I would also comment, to echo what Alec said, for the node-
negative cases, where most of the benefit or most of the very good
result at least was seen, you accumulated 43 patients in 26 years.
So I don’t see that we can be changing our practice right now,
except with what Steve just said, which is to use more modern
science to follow very selected patients. But clearly there are a
great many patients with clinically limited disease who have been
treated by our medical oncology colleagues. And it’s worth noting
that there has been tremendous progress, not only with platinum
but subsequently with hyperfractionated radiation schedules and
perhaps Current Procedural Terminology code 11. So the regimen
72 The Journal of Thoracic and Cardiovascular Surgery ● Januathat you propose is perhaps not the current state of the art in
nonsurgical oncology either.
Dr Patterson. Did you want a comment from the survivors of
the era, or survivors of the trial?
Dr Waddell. You would do fine.
Dr Patterson. Tom was mentioning the Frances Shepard trial.
It was a very small experience, as he said, and most of those
patients had IIIA disease. I mean those were N2 cases.
Dr David J. Sugarbaker (Boston, Mass). I wonder how many
of these you knew about preoperatively. Because usually you’re
resecting a solitary nodule, and you did a lobectomy, and after
frozen section, the pathologist says it was a malignant tumor.
Maybe you had done a mediastinoscopy and the results were
negative, so you went ahead and did a lobectomy. Most of us
would say in that case to give adjuvant therapy on the basis of the
data that are available, much of which are old. Unless we get some
sort of cooperative ability to get a large number of cases together,
isn’t that what we’re going to be stuck with, doing the lobectomy
and giving adjuvant therapy?
Dr Brock. Yes. I agree 100%. That’s exactly why we’re
proposing to get people together, maybe in an American College of
Surgeons Oncology Group trial or similar, where a large number of
institutions can come together and design a trial so that we’re not
“stuck” with an ineffective or out-dated therapy.
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